Control ALT, Delete Cancer

Age is the biggest risk factor for cancer, and as the life expectancy of the world’s population continues to increase, cancer incidence is also expected to rise dramatically. The 2011 Global Health and Aging Report, published by the National Institutes of Health and the World Health Organization, predicts that the number of people aged 65 and older will triple to 1.5 billion by 2050 and that the annual number of new cancer cases will reach 27 million by 2030. Undoubtedly, alleviating the frailty and diseases associated with an aging global population will require the development of new anticancer approaches to avoid economic and human disasters.
Treating cancer by shutting down the alternative lengthening of telomeres (ALT) pathway
Cellular immortality is a feature that helps distinguish cancerous tissues from normal tissue. Each time a normal somatic (body) cell divides, the DNA at the ends of its chromosomes, called telomeres, shortens. When a telomere becomes too short – which happens after 30-50 divisions – an alarm signal is generated and the cell permanently stops dividing. It then enters senescence or initiates apoptosis.

The mechanisms by which a cancer cell prevents telomere shortening
Telomere shortening each time a cell divides serves as a biological mechanism for limiting cellular lifespan. Cancer cells, on the other hand, use telomerase with an RNA template, or use a mechanism called alternative lengthening of telomeres (ALT) with a DNA template, to synthesize new telomeric DNA, activate the telomere maintenance mechanism (TMM) and potentially become immortal.
Note: The scientists Elizabeth H. Blackburn, Carol W.Greider and Jack W. Szostak were recognized for discovering how chromosomes are protected by telomeres and telomerase when they were awarded the 2009 Nobel Prize in Physiology or Medicine for that discovery.
Because the presence of a telomere maintenance mechanism is an almost universal feature of cancer cells, and experimentally suppressing these mechanisms results in cancer cell senescence or death, telomere maintenance mechanisms may be useful targets in cancer treatment. In fact, several treatments targeting the well-defined telomerase-based pathway are in advanced stages of clinical trials. However, there are currently no ALT-targeted drugs in active use because this process is not yet clearly understood.
ALT-supported cancers
Unlike the telomere lengthening that occurs in the stem cells of healthy tissues and organs, ALT activity is not normally found in postnatal tissues of healthy individuals. Every year, based on an estimate that 10% of cancers use an ALT strategy to achieve cellular immortality, ALT cancers account for approximately 1.4 million new cases and 820,000 deaths worldwide. These include some of the cancers that are more difficult to treat clinically, such as pediatric and adult brain cancers, soft tissue sarcoma, osteosarcoma and lung cancers. Clearly, targeting ALT is a very attractive strategy for developing new cancer treatments.
Furthermore, as with any cancer treatment, there is the potential for cancer to develop resistance to telomerase-based strategies. Several in vitro (laboratory) studies report that human cancer cell lines can overcome telomere loss by activating ALT. In mice, suppression of the telomerase enzyme has also been shown to cause existing tumors to activate the ALT pathway as telomeres shorten with treatment. Importantly, some human tumors have both ALT and telomerase activity, although not necessarily in the same cell at the same time. Thus, it is reasonable for telomerase-dependent cancer treatments to create selective pressure in tumors to activate the ALT pathway and/or select cells within the tumor that already use ALT, making the development of ALT-specific therapies a challenge for the success of anticancer approaches targeting telomere maintenance mechanisms.
A closer look at telomeres and changing cancer
Telomeres consist of repetitive hexameric DN sequences (5’ – TTAGGG – 3’) intertwined around a group of proteins known as the Shelterin Complex. These structures form a protective cap at the end of each chromosome. Because all telomeres contain the same repetitive DNA, new telomeric DNA can be produced by copying another molecule containing the telomeric sequence through homologous recombination.
One of the distinguishing features of ALT cancer cells is that they contain large amounts of telomeric repeat DNA separated from chromosomes. These extrachromosomal sequences, which may be linear or circular, can serve as templates for ALT-mediated telomere lengthening. The template may also be another telomere or the same telomere, such as the end of a sister chromatid that folds back on itself.
ALT activation is associated with the loss of important chromatin-remodeling proteins at telomeres, probably allowing the DNA damage response and homologous recombination machinery to initiate ALT activity. ALT activation is also accompanied by the abnormal association of certain nuclear proteins with telomeres, as well as replication used in meiosis. ALT and ALT-like mechanisms appear to be evolutionarily conserved from yeast to worms and humans. In fact, some yeast species contain mitochondria with linear genomes and telomere-like repeat sequences at their ends. These mitochondrial genomes maintain their telomeres through a recombination-based mechanism resembling that found in human cells using ALT. This raises the possibility that ALT evolved out of necessity to maintain stability in linear genomes after the transition from a circular form, before telomerase emerged as a TMM.
Studies in mice show that the recombination-mediated ALT mechanism is the main driver behind the telomere lengthening observed during the early stages of embryonic development. Telomere lengthening through ALT may also play a role in reprogramming murine somatic cells into induced pluripotent stem cells and in generating embryonic stem cells through somatic cell nuclear transfer. Cancers that activate the ALT mechanism may therefore be exploiting an important biological phenomenon to achieve immortality and cause harm. A better mechanistic understanding of the ALT pathway may thus contribute not only to more effective cancer treatments but also to a better understanding of genomic biological evolution.
- Related topic: Did you know that cancer evolves? Can it be prevented?
However, developing ALT-targeted therapies is very difficult. Unlike the telomerase pathway, the ALT mechanism has no known specific enzyme activity, and all enzymes identified to date as having a role in ALT are also required for normal cellular pathways. The presence of ALT activity has generally been inferred from the detection of telomere-related phenotypes, such as long and heterogeneous telomere length distributions or ALT-associated promyelocytic leukemia nuclear bodies (APBs), which show the abnormal presence of telomeres in a complex of otherwise ubiquitous nuclear proteins. (“Going Long” The Scientist, April 2014.) These markers are not entirely satisfactory because they can sometimes produce incorrect results and are not practical for high-throughput applications or clinical laboratories.
An important step toward developing ALT-targeted cancer therapeutics and diagnostics was the discovery of telomeric C-circles, the first ALT-specific molecule (Nat Biotechnol, 27:1181-85, 2009). C-circles are an unusual type of circular DNA formed from telomeres. The level of C-circles in cancer cells accurately reflects the level of ALT activity, and this biomarker can be found in the blood of patients with bone cancer who are positive for ALT activity. The development of C-circle analysis, together with improvements in APB analysis, may make it possible in the near future to perform robust, high-throughput screens for modulators of the ALT pathway, greatly accelerating the pace of discovery in this field. Further research will undoubtedly lead to a more complete mechanistic understanding of this phenomenon and to the first ALT-specific therapies against cancer. Controlling ALT may help erase the burden of cancer from society.
Sources
2. Sliva H. et al. (01.04.2015). Control ALT, Delete Cancer. The Scientist: https://www.the-scientist.com/
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.